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Abstract 
Telomerase maintains the length of telomeric DNA at the end of chromosomes; stabilizes the functions of 
chromosomes, protects the structure of chromosome DNA and regulates normal cell growth. The length 
and stability of telomeres determine the cellular lifespan. Moreover, they correlate with cellular aging and 
carcinogenesis. Researches on the role of telomerase in degenerative diseases and cancers show that it 
regulates cellular senescence. Although telomerase is not an oncogene, it does make tumor cells immortal 
by maintaining the stability of telomeric DNA. Telomerase-based therapies have become a hotspot in new 
anticancer and degenerative diseases treatments. This review aims to provide a comprehensive 
understanding of the role of telomerase and telomere in cellular senescence and cancer. 
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Introduction 
Telomeres are specialized structures located at the terminal ends of chromosomes and play a critical 
role in stabilization of chromosomes, maintaining the integrity of the genome [1,2], and regulation of 
normal cell growth. Telomerase is a reverse transcriptase enzyme which synthesizes the G-rich tandem 
repeats that comprise telomeres using a template on the RNA that is complementary to the telomeric 
repeat. By adding hexameric (TTAGGG) repeats, the continued erosion of telomeres is compensated. Over 
the past few decades, studies have shown that telomeres and telomerase are closely related to cellular 
malfunction, degenerative diseases and tumor progression. Therefore, researches into the role of 
telomerase and telomere in degenerative diseases and cancer shed light on a better understanding of these 
diseases. Telomerase-based therapies, including targeted agents will open up a whole new horizon for 
degenerative diseases and cancer treatments. 
Telomeres, telomerase and their relationship  
Telomere, from the Greek word “telos,” (end), and “meros,” (part) was first named by American 
geneticist Hermann J. Muller, who observed through mutation experiments carried out during the 1930s 
[3]. Telomeres which have specialized structures that repeat at the ends of chromosomes are thought to be 
important for the integrity and stability of chromosomes. This observation implied that cells contained an 
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enzyme that could catalyze the lengthening of chromosomal ends. In 1984, Elizabeth Blackburn discovered 
the enzyme telomerase in the ciliate Tetrahymena, which has the ability to lengthen chromosomal ends by 
its reverse transcriptase activity [4]. 
Telomeres DNA sequences are highly conservative and genus-species specific. Human telomeres contain 
an array of tandem DNA repeats (5’-TTAGGG-3’), which do not encode any gene product. The length of the 
telomere DNA repeats varies from about 5～15kp. These special DNA repeats combine their associated 
proteins to form the cap of chromosomes, which can prevent chromosome end-to-end fusion, degradation 
and rearrangement from happening, unless the free ends of the DNA molecule are processed as double 
stranded breaks [5]. To avoid chromosome damage, the end of telomeres forms two internal loops (D-loop 
and T-loop) with the participation of the shelterin complex [6]. Usually the shelterin complex is made up of 
six proteins which play different roles, including telomeric repeat-binding factors 1 and 2 (TRF1 and TRF2), 
TRF1-interacting nuclear factor 2 (TIN2), repressor activator protein 1 (Rap1), TIN2-interacting protein 1 
(TINT1) and protection of telomeres 1 protein (POT1). TRF1 and TRF2 bind to double stranded TTAGGG 
repeats, and the POT1 binds to the 3’ G-rich overhang. The three remaining factors contained TIN2, Rap1 
and TINT1, which interact with the telomere-bound proteins to form a complex. This allows cells to 
distinguish telomeres from sites of DNA damage [7-9]. Telomeres maintain the integrity of chromosomes. 
As the cell divides, about 100-200 bp of telomeric DNA sequence is lost. This phenomenon is so-called the 
“end replication problem”. When the DNA repeats strand becomes too short to form loops, the 
chromosome loses its endpoint protection [9]. This is why the telomeric repeats shorten progressively with 
each cell division [10]. If the telomeres are shortened enough, telomerase is activated to compensate for 
the end-replication problem [11], so that the length of telomeres is maintained. 
Human telomerase which is a ribonucleoprotein polymerase (RNP) composed of an essential RNA and 
associated proteins has important function. When chromosome loses its endpoint protection, telomerase is 
activated to catalyze the addition of TTAGGG nucleotide repeats to the 3’ terminus of the chromosome’s 
DNA [12], so that it guarantees the length and function of telomeres. In generally, the telomerase 
holoenzyme consists of three components: telomerase reverse transcriptase (TERT), the telomerase RNA 
component (TERC) and telomerase related proteins (TEP). The TERT and TERC are most important. TERC as 
a template can add a TTAGGG nucleotide repeat to the 3’ end of the telomere’s leading strand; TERT is 
taken to be the rate-limiting component of telomerase activity [13]. TERC varies greatly among species, but 
TERT is relatively conserved throughout evolution [14]. In humans, TERC contains 451 nucleotides, which 
includes an 11-nucleotide template and several conserved regions [13,15]. It can provide the template for 
the synthesis of telomere DNA repeats, and also plays essential roles in catalysis and accumulation of 
telomerase RNP. The TERT gene which located on chromosome 5, consists of 16 exons and 15 introns 
spanning 35 kb, including 330 base pairs upstream of the translation start site, as well as 37 base pairs of 
exon 2 of the TERT gene. The TERT promoter which contains many sites for several transcription factors is 
GC-rich and lacks TATA and CAAT. It is an important target for therapy of cancer and degenerative diseases. 
Telomerase has other related proteins (TEP), such as GAR1, NHP2 and NOP10. They are assembled in the 
telomerase complex and play distinctive roles in telomerase function [16]. 
The role of telomere and telomerase in degenerative diseases  
Telomere length shortening has been evidenced as not only a marker of biological aging but also a 
mechanism with important functional consequences. It has been considered as a risk factor for multiple 
aging-associated diseases and conditions. The study of telomere and telomerase biology shows a higher 
prevalence of development in many neurodegenerative diseases, such as Alzheimer’s disease (AD), 
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Parkinson’s disease (PD), CVD, hypertension, atherosclerosis, heart failure, diabetes and so on. This review 
focuses on providing a general understanding of the role of telomere and telomerase in Alzheimer’s disease 
(AD) and Parkinson’s disease (PD).  
Alzheimer’s disease and Parkinson’s disease are the two main aging-associated progressive 
neurodegenerative disorders. Studies show that they are related to telomere and telomerase. The 
relationship between telomere shortening and AD has been studied using in vitro and in vivo models in AD 
patients. Oxidative stress is regarded as the most important influencing factor of telomere shortening. 
There are some studies connecting the telomere length to Alzheimer’s disease. Panossian L. A. et al. [17] 
first found that patients with AD had shorter telomere lengths in peripheral blood mononuclear cells than 
that of the age-matched control subjects. Then, Jenkins E. C et al. [18] found that older females with Down 
syndrome and AD-type dementia had shorter T-cell telomeres than that of the age-matched counterpart. 
Moreover, a case control study of 257 individuals revealed a shortened peripheral blood leukocyte (PBL) 
telomere length in AD patients compared with control subjects [19]. And among individuals with AD, short 
telomeres were associated with higher mortality rates. Another study confirmed the association between 
short PBL telomere length and AD, and was the first to examine hippocampus telomere length in 
histopathologically validated AD patients [20]. Surprisingly, telomere lengths in the hippocampus were 
found to be 49 % longer in AD patients than in control subjects (P<0.01). Recently, J. Nicholas Lukens 
compared the telomere lengths in peripheral blood and cerebellum in Alzheimer’s disease and found that 
reduced PBL telomere length in AD might not reflect reduced telomere length in bulk brain tissue, but may 
be a marker of changes in a subset of brain tissues or other tissues that affect the pathogenesis of AD [21]. 
Telomerase activity in AD patients was significantly elevated compared with healthy controls and vascular 
dementia patients, possibly as a response to the telomere erosion accompanying the disease. In addition, 
the telomerase activity of lymphocytes was significantly correlated with the degree of dementia in AD 
patients, suggesting an accelerated telomere dysfunction in lymphocytes and impaired immune function of 
AD patients. 
The relationship between telomere and PD is not well clear. Several studies have shown that telomere 
and telomerase are related to PD, but other studies indicate that there are no evidence for short telomere 
length in PD. Wang et al. [22] proved that men with shorter telomeres had a lower risk for PD, which was in 
marked contrast with the observations in other aging-related diseases. In a study of 28 Japanese male PD 
patients, leucocyte telomere length in PD patients was not significant different from those in controls. But 
mean telomere length in PD patients was found to be 5 kb shorter suggesting telomere shortening was 
accelerated in PD patients [23]. Additionally, Maede et al. [24] investigated the age-associated alterations 
of subtelomeric methylation in Japanese PD patients. Short telomeres with hypomethylated subtelomeres 
increased with aging in the healthy controls, but did not change in the PD patients. Johanna Eerola et al 
analyzed 131 PD patients and 115 controls. It was found that extremely short telomeres were not more 
frequent in PD patients than in controls, so they consider there was no evidence for shorter leukocyte 
telomere length in PD [25,26].  
The role of telomere and telomerase in neurodegenerative diseases is not fully understood through 
above researches, despite the progress made during the last decade. Further research is essential to clarify 
whether the AD and PD are triggered by telomere shortening. 
The role of telomere and telomerase in cancer  
Telomere studies in human cancer have been extensively reported for diagnostics and prognostics. 
Shortened telomere length demonstrates a significant association with poor cancer outcome [27]. 
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Telomere maintenance is regarded as an important mechanism in evading senescence by cancer cells, and 
the role of dysfunctional telomere biology in cancer is acknowledged. Many cancer cases were initiated by 
reactivating or up-regulating telomerase activity. In addition, in many types of cancer cell, there is a 
considerable shortening of telomeres despite telomerase expression [28-32]. Based on these researches, 
several anti-cancer drugs and cancer vaccines that target the telomerase are used now in phase III clinical 
trials. 
The relations between telomere, telomerase and cancer have been a hot research topic. Cancers occur 
when a cell acquires multiple genetic mutations which cause the cell to escape from normal controls on 
replication and migration. Once the cells and their offspring multiply uncontrollably, they can invade and 
damage nearby tissue. Some may also break away and travel to parts of the body where they do not 
belong, resulting in new metastases at distant sites. The lack of telomerase in tumor cells may slow the 
growth with dividing cells, and lose their telomeres before they do much damage. On the other hand, if 
cancer cells were able to generate telomerase, they could retain telomeres and might growth indefinitely. 
Researchers suspect that the loss of proliferative capacity observed in human cells that lacking telomerase 
may help us to avoid cancer. Here, we direct our attention to digestive cancers, telomere and telomerase. 
Telomerase activity is especially considered as the most important factor in carcinogenesis, progression 
and prognosis. Fundamental researches showed that telomerase was activated in various cancer tissues 
and cell lines [33-35]. Telomerase activity was shown to be positive in 85 %～100 % of cancer tissues and 
negative in almost all normal tissues, except for reproductive and haemopoietic cells. In digestive cancers, 
many studies regard telomerase activity and telomere length are associated with the occurrences of 
cancer, and as prognostic markers in malignancies. Studies indicate telomerase activity is detected in 85 % 
of the hepatocellular carcinoma specimens [36], 85 %～88 % of gastric carcinomatous tissues [37], and 90 
% of colorectal tumors [38]. In gastrointestinal cancer, human telomerase are expressed in various levels 
between all tumor specimens and normal mucosa. For instance, the expression of telomerase is 81% higher 
in the tumor than normal mucosa. Meanwhile 35 % of normal mucosa showed telomerase activity and all 
of them contained intestinal metaplasia [39,40]. The study by Engelhardt M indicated that increased 
telomerase activity occurs in colon cancer cells that have undergone extensive telomere shortening relative 
to surrounding normal tissues, in which telomerase-induced stabilization of telomeres may be critical for 
the continued proliferation of the malignant clone [38]. The link between telomerase activity and stage 
suggests that telomerase is up-regulated as a function of increased tumor cell invasion, tumor progression, 
and metastatic potential in colon cancer. On the research of prognosis, telomere length could be a 
potential unique biomarker predictive of clinical benefit (i.e. progression free survival) of mCRC patients 
treated with anti-EGFR therapy [41]. The high level of telomerase activity may be an independent 
prognosis-predicting factor in the patients with colorectal cancer [42]. 
Prospect 
To sum up, the related research shows that the occurrence and changes of degenerative diseases is 
closely related to telomere shortening. Especially, the study for patients with Alzheimer and Parkinson 
shows that the dysfunction of telomerase activity and telomere shortening which may lead to the 
occurrence of these disease and relate to the severity of the disease. Through the study of telomerase 
activity, it may be possible to find new ways of treatment for these two diseases. In addition, there are 
studies to explore the relationships and related mechanisms between tumor and telomere, telomerase. 
Telomerase activation and telomere shortening are closely related to the occurrence and development of 
malignant tumor. Currently, the study of telomerase targeted drugs for the treatment of cancer has 
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entered the phase III clinical trials. Hopefully findings from these studies will emerge as a new approach for 
cancer therapy. 
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